951 A phase 1 first in human study of adenovirally transduced anti-HER2 CAR macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data

• Michael Klichinsky,
• Thomas Condamine,
• Kim Reiss,
• Debora Barton,
• Amy Ronczka,
• Daniel Cushing,
• Sascha Abramson,
• Rehman Qureshi,
• Elizabeth Dees

Affiliations

Michael Klichinsky

Carisma Therapeutics, Philadelphia, PA, USA

Thomas Condamine

2Incyte Corporation, Wilmington, DE, USA

Kim Reiss

1University of Pennsylvania, Philadelphia, PA, USA

Debora Barton

3Carisma Therapeutics, Springfield, NJ, USA

Amy Ronczka

3Carisma Therapeutics, Springfield, NJ, USA

Daniel Cushing

3Carisma Therapeutics, Springfield, NJ, USA

Sascha Abramson

3Carisma Therapeutics, Springfield, NJ, USA

Rehman Qureshi

3Carisma Therapeutics, Springfield, NJ, USA

Elizabeth Dees

4UNC, Chapel Hill, NC, USA